Market News

Henrik Stenqvist will be based at the company's HQ in Sweden.

Collaboration to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications.

Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling.

Industry leading further education programs unified and expanded.

Company has achieved an annual energy intensity improvement of more than 3% globally, contributing to an 11.4% reduction in energy consumption since 2010.

Bosch showcases i4.0 solutions live at Interpack.

Agreement terms are "favourable for both parties".

ECF843 is a new therapeutic approach and potential first-in-class Rx treatment in dry-eye.

RedHill expects to initiate US promotion of its two commercially-available gastrointestinal specialty products, Donnatal and EnteraGam, in mid-2017.

Greater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.

First launch of product using FOX smart nebuliser.

David Meeker will leave the company at the end of June after a 23-year career with Genzyme and Sanofi.

The five-fold increase in capacity reflects growing demand for cold chain services.

Kit for confirming successful antibody-biotin conjugation.

Company's CAPA addresses the three Form 483 observations.

Will fund a new manufacturing, packaging and distribution facility.

Represents the latest combination therapy now available for the millions of patients living with COPD in the US.

New magnetic resonance technologies and applications open new frontiers for biological, chemical and materials research and routine analysis in pharmaceutical and chemical industries.

Recall will extend to additional markets in Europe, Asia, North and South America.

Installation of state-of-the-art Harro Hӧfliger encapsulation unit expands clinical- and commercial-scale capacity for dry powder inhalation applications.

ImpactAir high performance air sampler range joins Cherwell’s portfolio of cleanroom microbiology products.

Inspection of up to 600 glass containers per minute using unique group testing.

Cold-EEZE is now Mylan's largest US consumer healthcare brand.

Part of a longer term plan to increase capacity.

Offers more flexibility, better supply predictability and shorter lead times for more efficient and safer drug manufacture.

System can achieve separations with higher resolution, reproducibility and recovery then has previously been possible.

Canada first country to launch Fiasp.

Provides a cleaner, renewable energy source to reduce costs and lessen the CRO facility's impact on the environment.

First NCE approved for PD patients with motor fluctuations in the US in more than a decade .

Significant investment in manufacturing diabetes medicines continues with new $85 million commitment in Indianapolis.

More than 80 contract manufactures were assessed by 26 performance metrics in ISR’s annual Contract Manufacturing Quality Benchmarking survey.

Developments correspond to generic products based on specialized pharmaceutical technologies.

Partnership to collaborate with industry to reduce risk and ensure optimal compliance for all members of the pharmaceutical supply chain.

New site will be used to complete premium injectable elastomeric component manufacturing.

The two new systems offer faster method development and the ability to quantify multiple proteins simultaneously.

PharmaCote ECxtra eliminates problems encountered during the hard chromium coating process.

5800-m2 facility will provide a range of GMP pharmaceutical testing services.

CDMO will manufacture and deliver Emla Patch - a local anaesthetic product.

TLE400 is a fixed-combination containing Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 400 mg/300 mg/300 mg.

Greater filtration capacity with a smaller footprint than conventional filters, improving economics for biopharmaceutical manufacturing.

Amgen has announced that the 27,564-patient Repatha (evolocumab) cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible wit...

PIC/S membership accelerating international interest with market forecast to reach US$115bn by 2024.

The Xelum platform combines dosing, mixing, granulating and pressing, paving the way for more efficient tablet manufacturing.

Cinryze is the first and only Hereditary angioedema treatment approved for routine prevention in paediatrics.

Supports small molecule ion channel drug discovery, from initial screening to development candidate.

For success in the biosimilars sector, manufacturers must adopt QbD, DoE and PAT initiatives.

Alliance brings together eye care and CRISPR innovators to develop transformative medicines for patients.

Zavicefta treat complicated infections caused By Gram-negative bacteria.

Current product portfolio includes a range of specialty alkoxide bases and borane derivatives.

Settlement provides Mylan with global licenses for its trastuzumab product.

Work on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.

The tablets are indicated for the treatment of major depressive disorder.

Collaboration is the second to evaluate a combination of CV301 with a checkpoint inhibitor.

Tooling products focused on increasing productivity for the tablet manufacturer.

Partnership formed to evaluate the impact of Amplycell’s novel cell fitness technology on expression capacity of Horizon’s bioproduction cell line.

Expansion plan comprises company's largest investment in the US.

The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons and parenteral kits, as well as unit dose wallets and child resistant/compliance prompting packaging.

He succeeds Dr Francis Cuss, 62, who will retire from the company.

Vertex to develop CTP-656 for potential use in future combination regimens aimed at treating the underlying cause of CF.

Alcami will use the D8 DISCOVER HTS to add XRD capabilities to their laboratory service portfolio.

Merck's €42 million investment expands the allergies business on a global scale.

MEDI8897 has been engineered to have a long half-life so that only one dose would be needed for the entire RSV season.

Reinforces position as a supplier of excipients and raw materials for the pharmaceutical and biopharmaceutical industries.

Funding will be used to prepare for international clinical study to evaluate the Company’s ELISA-based urine test for prostate cancer.

Affinivax’s MAPS vaccine technology overcomes the limitations of current conjugate vaccine technology, creating a MAPS pneumococcal vaccine that enables broader protection.

Government plans to construct 10 factories for the manufacturing of biosimilars by 2020, with an additional investment of $265.3 million.

Acquisition enhances Lilly's existing pain management.

Innovation is being driven increasingly by smaller, possibly more agile, companies.

Supports a wide range of needs across the biopharma development cycle.

New model incorporates an improved algorithm to simplify test creation and accelerate test completion.

Partnership leverages Lonza's expertise in large-scale mammalian cell culture facilities alongside Sanofi's strength in developing and launching biologics based treatments.

Recall due to potential lack of sterility assurance.

Tool explores the time course of drug exposure, biomarker response and outcome.

Portfolio includes treatments for Crohn's disease, ulcerative colitis, and bowel preparation before endoscopy.

Approval of the automated mini-doser marks first hands-free administration option for a PCSK9 inhibitor in Europe.

Aids R&D initiatives to advance precision medicine.

EP Vantage Releases its Annual Pharma and Medtech Sector Review Reports for 2016.

New kit enables covalent conjugation of antibodies and proteins to magnetic particles.

The acquired business is now known as Recipharm Pharmaservices Private Ltd.

Distributors, API manufacturers, and machinery providers seeing high demand across Russia and CIS.

Unique sensor technology tracks inhalation profiles and technique.

Sartorius is offering its expertise to enhance scientific education and practice.

Company achieves the £9 million calendar year royalty cap on net sales of Ellipta products a year earlier than previously guided.

Expands softgel development and manufacturing capabilities and capacity.

The proposed biosimilar to Neulasta is used to reduce the duration of neutropenia and the incidence of fever associated with neutropenia in adult patients treated with chemotherapy in certain types of cancer.

Investment in a inductively coupled plasma mass spectrometry system is a move to address the updated ICH Q3D regulatory guidelines on elemental impurities.

Trends include ‘human factor’ principles, with ‘individualised packaging and serialisation’ as the integral solutions of the future.

Generic Pharmaceutical Association becomes Association for Accessible Medicines.

Complidermol 5α PLUS tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.

Acquisition paves the way for Quotient to replicate its Translational Pharmaceutics platform in America.

Symbiosis Pharma now able to offer East and West Coast clients small-scale aseptic manufacturing capabilities to support clinical trials.

Easyhaler is a dry powder inhaler for the treatment of asthma and COPD.

The Expanding role of pharmacovigilance in rapidly changing regulatory and commercial climates.

Foresee technology can help to develop stable, formulated peptides in solution for controlled-release therapy for 3- and 6-month durations of action after a single injection.

Favourable macro trends will be reflected at CPHI South East Asia where domestic manufacturers are increasingly attending the event, with a view to opening up sales in international markets.

The initial US$1.3 million order is to supply components for ultra low temperature robotic storage systems in the US to major pharmaceutical companies.

PharmaCote ECxtra has been developed to stop the issues encountered by hard chrome, but still provide a coating that provides excellent tooling protection.

Praluent continues to be available to patients in the US.

Partnership to explore and identify new tools and methods to modify and optimize the CHO cell line performance.

IDT expands its capacity for direct sales of genomic products in Asia-Pacific region.

GSK launches Flonase Sensimist allergy relief nationwide.

Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist injectable prescription medicine.

Company to introduce its portfolio of generics in France.

Vial injector, pharma compliance pack, smart packaging and autoinjector for prefilled syringes named best innovations in 2017.

The partnership will integrate Genedata Screener software with TTP Labtech’s acumen Cellista and mirrorball to improve screening data management.

Personal medical device leveraging "Internet of Things" technologies to address medication adherence.

By the end of 2017, company plans to increase to 230 process chemists and 70 analytical chemists.

Acquisition of Extrakt Chemie and site investments in people, equipment, manufacturing buildings and new offices increases company's position in Germany.

The growing number of states and countries getting approval for using marijuana in therapeutic applications is a crucial factor driving the demand over the coming few years.

A team of industry experts reward Nemera’s autoinjector with a Pharmapack Award as best innovation product.

Opdivo has now been approved in six tumour types in just over 2 years.

The company’s growth has been driven by export, with a three-fold increase in activity outside of the UK during 2016,

Rentschler will become the first and only CDMO to have access to Leukocare's patented SPS formulation technologies.

Acquisition provides fully equipped facilities for the development and manufacture of clinical stage cellular therapy products, including three ISO7 cGMP manufacturing suites, extensive flow cytometry and analytical infrastructure.

The Dublin offices are the company's first permanent business premises outside of North America.

Patent found to be invalid.

Acquisition creates world-class aesthetic and regenerative medicine business in plastic surgery.

Bioverativ common stock to be traded on the NASDAQ global select market.

Xyzal is an oral antihistamine with a proven 24-hour effect.